Pricing Log in Create free account
Friday 6 November 2026 Export PVLA’s income statement to Excel — free account

Palvella Therapeutics, Inc.

PVLA Healthcare Biotechnology

Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.

EPS
−76.7%
Free cash flow
−136.4%

Quarter to June 2026, against a year earlier

173.38 16.53 +10.54%
Market cap
$2.3B
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
2/9
Altman Z
−11.49
Beneish M
1.44
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Palvella Therapeutics, Inc. (PVLA) P/E ratio

Alert me on P/E ratio

Palvella Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —
FY2015 0.0× —

Quarterly newest first

Period P/E ratio Change
Mar 2024 0.0× —
Dec 2023 0.0× —
Sep 2023 0.0× —
Jun 2023 0.0× —
33 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
PVLA Palvella Therapeutics, Inc. n/m
PHVS Pharvaris N.V. compare n/m
BHVN Biohaven Ltd. compare n/m
VERA Vera Therapeutics, Inc. compare n/m
CLDX Celldex Therapeutics, Inc. compare n/m
IMNM Immunome, Inc. compare n/m
AUPH Aurinia Pharmaceuticals Inc compare 6.8×
ADMA ADMA Biologics Inc compare 16.7×
VCEL Vericel Corporation compare 77.8×
Biotechnology industry median 10.3×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on PVLA